GT Biopharma, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:GTBP) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 2.66 M7.12 M4.32 M8.11 M10 M5.79 M Total liabilities 3.64 M2.31 M1.32 M2.32 M2.42 M2.22 M Total equity -980 K2.86 M3 M5.79 M7.58 M3.57 M Total liabilities & shareholders' equities 2.66 M7.12 M4.32 M8.11 M10 M5.79 M Total debt —————— Net debt ——————

News

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting

GT Biopharma submits IND application for solid tumor cancer treatment

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - GT Biopharma (NASDAQ:GTBP)

GT Biopharma stock rises as Phase 1 trial advances to higher dose

Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Cycurion (NASDAQ:CYCU), Clearwater Analytics Hldg (NYSE:CWAN)

GT Biopharma advances to Cohort 4 in Phase 1 trial of cancer therapy

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics (NASDAQ:APGE), Ambow Education Holding (AMEX:AMBO)

EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - GT Biopharma (NASDAQ:GTBP)

GT Biopharma holders waive redemption rights on Series L preferred stock

GT Biopharma begins dosing in cohort 3 of cancer treatment trial